BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36430338)

  • 1. Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex.
    Hu Z; Marti J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
    Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
    J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
    Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal Packing Reveals a Potential Autoinhibited KRAS Dimer Interface and a Strategy for Small-Molecule Inhibition of RAS Signaling.
    Brenner RJ; Landgraf AD; Bum-Erdene K; Gonzalez-Gutierrez G; Meroueh SO
    Biochemistry; 2023 Nov; 62(22):3206-3213. PubMed ID: 37938120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
    Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
    Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
    Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
    Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
    Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next batter up! Targeting cancers with KRAS-G12D mutations.
    Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
    Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
    Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
    J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugging an undruggable pocket on KRAS.
    Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
    Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Dynamics Allows Sampling of an "Active-like" State by Oncogenic K-Ras-GDP.
    Grudzien P; Jang H; Leschinsky N; Nussinov R; Gaponenko V
    J Mol Biol; 2022 Sep; 434(17):167695. PubMed ID: 35752212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
    Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
    Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
    Hu X; Zhang R; Yao J; Mu B; Zhao C
    Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific mutagenesis screening in KRAS
    Choi J; Shin JY; Kim TK; Kim K; Kim J; Jeon E; Park J; Han YD; Kim KA; Sim T; Kim HK; Kim HS
    Cancer Lett; 2024 Jun; 591():216904. PubMed ID: 38642608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic G12D mutation alters local conformations and dynamics of K-Ras.
    Vatansever S; Erman B; Gümüş ZH
    Sci Rep; 2019 Aug; 9(1):11730. PubMed ID: 31409810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
    Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
    Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the conformational variability of oncogenic GTP-bound G12D mutated KRas-4B proteins at zwitterionic model cell membranes.
    Lu H; Martí J
    Nanoscale; 2022 Feb; 14(8):3148-3158. PubMed ID: 35142321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
    Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
    J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.